0.3651
前日終値:
$0.3497
開ける:
$0.3498
24時間の取引高:
1.20M
Relative Volume:
0.58
時価総額:
$21.41M
収益:
-
当期純損益:
$-98.79M
株価収益率:
-0.1117
EPS:
-3.27
ネットキャッシュフロー:
$-51.66M
1週間 パフォーマンス:
-43.40%
1か月 パフォーマンス:
+20.46%
6か月 パフォーマンス:
-89.54%
1年 パフォーマンス:
-90.19%
Relmada Therapeutics Inc Stock (RLMD) Company Profile
名前
Relmada Therapeutics Inc
セクター
電話
646 876 3459
住所
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY
RLMD を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
3.03 | 0 | 0 | 0 | 0 | 0.00 | |
![]()
GOODO
Gladstone Commercial Corporation
|
20.23 | 372.90M | 0 | 0 | 0 | 0.00 |
![]()
PSNYW
Polestar Automotive Holding Uk
|
0.1601 | 355.59M | 2.07B | -1.42B | -1.37B | -0.6765 |
![]()
MOBBW
Mobilicom Limited Warrants
|
0.2199 | 318.40M | 0 | 0 | 0 | 0.00 |
![]()
JUNE
Dhandho Junoon Etf
|
11.50 | 211.65M | 0 | 0 | 0 | 0.00 |
![]()
SHMD
Schmid Group N V
|
4.00 | 156.75M | 0 | 0 | 0 | 0.00 |
Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-12-05 | ダウングレード | Mizuho | Outperform → Neutral |
2024-09-17 | アップグレード | Jefferies | Hold → Buy |
2024-06-05 | ダウングレード | Goldman | Neutral → Sell |
2022-10-14 | ダウングレード | Goldman | Buy → Neutral |
2022-10-14 | ダウングレード | Guggenheim | Buy → Neutral |
2022-10-14 | ダウングレード | Truist | Buy → Hold |
2022-10-13 | ダウングレード | Oppenheimer | Outperform → Perform |
2021-11-18 | 開始されました | Mizuho | Buy |
2021-05-20 | 再開されました | Goldman | Buy |
2020-10-28 | ダウングレード | Goldman | Buy → Neutral |
2020-07-14 | 開始されました | Oppenheimer | Outperform |
2020-05-04 | 開始されました | SunTrust | Buy |
2020-04-21 | 開始されました | Goldman | Buy |
2020-01-27 | 開始されました | Jefferies | Buy |
2020-01-10 | 開始されました | SVB Leerink | Outperform |
2019-12-16 | 開始されました | Guggenheim | Buy |
すべてを表示
Relmada Therapeutics Inc (RLMD) 最新ニュース
Relmada Therapeutics Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView
Chief Executive Officer TRAVERSA SERGIO acquire 51,407 shares of Relmada Therapeutics Inc [RLMD] - knoxdaily.com
It makes sense and dollars to buy Relmada Therapeutics Inc (RLMD) stock - Sete News
AbbVie’s Rinvoq is approved in giant cell arteritis; Relmada shares bladder cancer data - Endpoints News
Market Insights: Relmada Therapeutics Inc (RLMD)’s Notable Drop of -44.64, Closing at 0.36 - DWinneX
Relmada Therapeutics (RLMD) Reports Promising Phase 2 Results fo - GuruFocus
Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Da - GuruFocus
Taking a Closer Look At Relmada Therapeutics Inc (RLMD) Following Its Recent Trade - knoxdaily.com
Relmada Therapeutics Reports 'Positive' Phase 2 Data for Bladder Cancer Treatment - marketscreener.com
Relmada Therapeutics, Inc. Presents Positive Initial Phase 2 NDV-01 Data at AUA2025 - marketscreener.com
Relmada reports strong Phase 2 results for bladder cancer drug By Investing.com - Investing.com Canada
Relmada reports strong Phase 2 results for bladder cancer drug - Investing.com
SEC Form 424B5 filed by Relmada Therapeutics Inc. - Quantisnow
Relmada Therapeutics (RLMD) Presents Positive Initial Phase 2 NDV-01 Data - StreetInsider
Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025 - Quantisnow
Breakthrough: Relmada's New Bladder Cancer Drug Achieves 90% Disease-Free Rate in Phase 2 Trial - Stock Titan
Relmada Therapeutics Inc: Rising -85.57% from 52-Week Low, Can the Stock Stay Afloat? - investchronicle.com
Relmada Therapeutics (RLMD) to Discuss NDV-01 Phase 2 Study Resu - GuruFocus
UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025 - GuruFocus
Relmada Therapeutics Presents NDV-01 Data at AUA2025 Conference for High-Risk Non-Muscle Invasive Bladder Cancer - Nasdaq
Groundbreaking Bladder Cancer Treatment Data: Relmada's NDV-01 Takes Center Stage at AUA2025 - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
Stock Performance Spotlight: Relmada Therapeutics Inc (RLMD) Ends the Day at 0.74, Up by 6.86 - DWinneX
Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data - The Manila Times
Bridgeline Digital Secures Elite SOC 2 Type II Certification: What This Means for Enterprise Security - Stock Titan
Take off with Relmada Therapeutics Inc (RLMD): Get ready for trading - Sete News
RLMD’s price-to-free cash flow ratio: What it means for investors - uspostnews.com
Relmada Therapeutics Inc (RLMD) receives a Neutral rating from Mizuho - knoxdaily.com
RLMD Stock: A Comprehensive Analysis and Forecast - investchronicle.com
Relmada Therapeutics (NASDAQ:RLMD) Trading Down 0.8% – Should You Sell? - Defense World
Relmada Therapeutics To Present NDV-01 Data at AUA2025 | RLMD St - GuruFocus
UPDATE — Relmada Therapeutics To Present NDV-01 Data at AUA2025 - TradingView
Revolutionary Cancer Therapy NDV-01 Data: Game-Changing Results Coming to AUA2025 - Stock Titan
Relmada Therapeutics To Present NDV-01 Data at AUA2025 - Yahoo Finance
Relmada outlines plans for NDV-01 Phase 2 results presentation and sepranolone development - MSN
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2024 Earnings Call Transcript - Insider Monkey
Relmada Therapeutics: Strategic Acquisitions and Pipeline Progress - TipRanks
Relmada Therapeutics pivots from psilocybin to cancer, neurological disorders - Crain's Chicago Business
Relmada Therapeutics Inc (RLMD) Q4 2024 Earnings Call Highlights: Strategic Acquisitions and ... - Yahoo
Relmada Therapeutics Inc (RLMD) Q4 2024 Earnings Call Highlights - GuruFocus
Relmada Therapeutics Reports 2024 Financial Results and Strategic Progress - TipRanks
Earnings call transcript: Relmada Therapeutics Q4 2024 sees improved EPS By Investing.com - Investing.com South Africa
Earnings call transcript: Relmada Therapeutics Q4 2024 sees improved EPS - Investing.com India
RELMADA THERAPEUTICS Earnings Results: $RLMD Reports Quarterly Earnings - Nasdaq
Relmada Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update - The Manila Times
Relmada Cuts Losses by 25%: Key Pipeline Programs Hit Critical Phase in 2025 - Stock Titan
Relmada Therapeutics Inc -On March 24, Enters Exclusive License Agreement With Trigone PharmaSEC Filing - MarketScreener
Insights Ahead: Relmada Therapeutics's Quarterly EarningsRelmada Therapeutics (NASDAQ:RLMD) - Benzinga
Mizuho maintains Relmada stock neutral with $1.00 target By Investing.com - Investing.com Canada
Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025 - Quantisnow
Relmada Therapeutics Inc (RLMD) 財務データ
収益
当期純利益
現金流量
EPS
Relmada Therapeutics Inc (RLMD) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
TRAVERSA SERGIO | Chief Executive Officer |
Sep 09 '24 |
Buy |
2.71 |
55,579 |
150,619 |
299,603 |
TRAVERSA SERGIO | Chief Executive Officer |
Sep 10 '24 |
Buy |
2.75 |
33,014 |
90,788 |
332,617 |
CASAMENTO CHARLES J | Director |
Sep 09 '24 |
Buy |
2.56 |
13,000 |
33,280 |
13,000 |
Shenouda Maged | Chief Financial Officer |
Sep 11 '24 |
Buy |
2.95 |
24,120 |
71,154 |
88,335 |
Shenouda Maged | Chief Financial Officer |
Sep 10 '24 |
Buy |
2.73 |
21,118 |
57,652 |
64,215 |
Shenouda Maged | Chief Financial Officer |
Sep 09 '24 |
Buy |
2.55 |
8,194 |
20,895 |
43,097 |
Kelly Paul Edward | Director |
Sep 09 '24 |
Buy |
2.59 |
25,000 |
64,750 |
212,295 |
大文字化:
|
ボリューム (24 時間):